Curative Biotechnology Dividend Yield

What does Curative Biotechnology do? Curative Biotechnology Inc. generates revenue through its software solutions for the healthcare market, targeting healthcare providers and institutions. The company focuses on developing therapeutic drug candidates, particularly in degenerative eye disease, with its lead product being a Metformin Reformulation for intermediate and late-stage age-related macular degeneration (AMD). Additional pipeline products include IMT504 for rabies, CURB906 for cancer treatment, and a COVID Vaccine with IMT504 Adjuvant, all developed under its concentrated therapeutic areas of degenerative eye disease, infectious disease, and neuro oncology. The company's degenerative eye disease platform drives its primary revenue stream, with the Metformin Reformulation targeting AMD patients. IMT504 serves infectious disease indications, specifically late-stage rabies, while CURB906 addresses neuro oncology through targeted cancer therapy. The pipeline products collectively cater to healthcare providers seeking innovative treatments for rare and complex conditions. Curative Biotechnology Inc. monetizes its drug development pipeline by advancing its therapeutic candidates through clinical stages, aiming for regulatory approvals and subsequent commercialization. Its focus on rare disease indications, including AMD and rabies, aligns with high-value therapeutic markets, positioning the company to secure partnerships and licensing deals with pharmaceutical firms and healthcare institutions. Curative Biotechnology is one of the most popular companies on Eulerpool.